Cargando…

Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats

Although parathyroid hormone (PTH) expresses an anabolic effect on bone mass, the increased bone mass disappears once PTH treatment is withdrawn. Therefore, sequential treatment with anti-bone-resorptive agents is required to maintain bone mass after PTH treatment. We examined the effect of sequenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Satoshi, Sakai, Sadaoki, Tanaka, Keisuke, Tomizawa, Haruna, Serizawa, Kenichi, Yogo, Kenji, Urayama, Koji, Hashimoto, Junko, Endo, Koichi, Matsumoto, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486915/
https://www.ncbi.nlm.nih.gov/pubmed/28246925
http://dx.doi.org/10.1007/s00223-017-0255-6
_version_ 1783246359871094784
author Takeda, Satoshi
Sakai, Sadaoki
Tanaka, Keisuke
Tomizawa, Haruna
Serizawa, Kenichi
Yogo, Kenji
Urayama, Koji
Hashimoto, Junko
Endo, Koichi
Matsumoto, Yoshihiro
author_facet Takeda, Satoshi
Sakai, Sadaoki
Tanaka, Keisuke
Tomizawa, Haruna
Serizawa, Kenichi
Yogo, Kenji
Urayama, Koji
Hashimoto, Junko
Endo, Koichi
Matsumoto, Yoshihiro
author_sort Takeda, Satoshi
collection PubMed
description Although parathyroid hormone (PTH) expresses an anabolic effect on bone mass, the increased bone mass disappears once PTH treatment is withdrawn. Therefore, sequential treatment with anti-bone-resorptive agents is required to maintain bone mass after PTH treatment. We examined the effect of sequential treatment with ibandronate (IBN), a nitrogen-containing bisphosphonate, following PTH in ovariectomized (OVX) rats. Wistar-Imamichi rats (27 weeks old) were ovariectomized and treated with PTH (10 µg/kg, s.c.; 5 times/week; PTH group) for 8 weeks from 8 weeks after OVX. Thereafter, PTH was withdrawn and rats were administered IBN (10 µg/kg, s.c.; every 4 weeks; PTH-IBN group) or vehicle (PTH-Veh group) for another 8 weeks. PTH increased bone mineral density (BMD) measured by dual-energy X-ray absorptiometry and biomechanical strength in the lumbar spine and femur as compared to the disease control rats. BMD and biomechanical strength in the PTH-Veh group were lower than in the PTH group, whereas in the PTH-IBN group they were maintained at the level of the PTH group. Microstructure of the trabecular and cortical bone in the PTH-IBN group was not significantly different from that in the PTH group. In histomorphometric analysis of the lumbar vertebra, eroded surface and osteoclast surface in the PTH-Veh group were no different from those in the PTH group, whereas they were lower in the PTH-IBN group. Osteoid surface, osteoblast surface, and mineralize surface decreased in both PTH-IBN and PTH-Veh groups compared to the PTH group, and these parameters in the PTH-IBN group were lower than in the PTH-Veh group. These results indicated that intermittent IBN after PTH treatment suppressed bone turnover and maintained BMD, biomechanical strength, and microstructure in the lumbar spine and femur of OVX rats.
format Online
Article
Text
id pubmed-5486915
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-54869152017-07-17 Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats Takeda, Satoshi Sakai, Sadaoki Tanaka, Keisuke Tomizawa, Haruna Serizawa, Kenichi Yogo, Kenji Urayama, Koji Hashimoto, Junko Endo, Koichi Matsumoto, Yoshihiro Calcif Tissue Int Original Research Although parathyroid hormone (PTH) expresses an anabolic effect on bone mass, the increased bone mass disappears once PTH treatment is withdrawn. Therefore, sequential treatment with anti-bone-resorptive agents is required to maintain bone mass after PTH treatment. We examined the effect of sequential treatment with ibandronate (IBN), a nitrogen-containing bisphosphonate, following PTH in ovariectomized (OVX) rats. Wistar-Imamichi rats (27 weeks old) were ovariectomized and treated with PTH (10 µg/kg, s.c.; 5 times/week; PTH group) for 8 weeks from 8 weeks after OVX. Thereafter, PTH was withdrawn and rats were administered IBN (10 µg/kg, s.c.; every 4 weeks; PTH-IBN group) or vehicle (PTH-Veh group) for another 8 weeks. PTH increased bone mineral density (BMD) measured by dual-energy X-ray absorptiometry and biomechanical strength in the lumbar spine and femur as compared to the disease control rats. BMD and biomechanical strength in the PTH-Veh group were lower than in the PTH group, whereas in the PTH-IBN group they were maintained at the level of the PTH group. Microstructure of the trabecular and cortical bone in the PTH-IBN group was not significantly different from that in the PTH group. In histomorphometric analysis of the lumbar vertebra, eroded surface and osteoclast surface in the PTH-Veh group were no different from those in the PTH group, whereas they were lower in the PTH-IBN group. Osteoid surface, osteoblast surface, and mineralize surface decreased in both PTH-IBN and PTH-Veh groups compared to the PTH group, and these parameters in the PTH-IBN group were lower than in the PTH-Veh group. These results indicated that intermittent IBN after PTH treatment suppressed bone turnover and maintained BMD, biomechanical strength, and microstructure in the lumbar spine and femur of OVX rats. Springer US 2017-02-28 2017 /pmc/articles/PMC5486915/ /pubmed/28246925 http://dx.doi.org/10.1007/s00223-017-0255-6 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Takeda, Satoshi
Sakai, Sadaoki
Tanaka, Keisuke
Tomizawa, Haruna
Serizawa, Kenichi
Yogo, Kenji
Urayama, Koji
Hashimoto, Junko
Endo, Koichi
Matsumoto, Yoshihiro
Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats
title Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats
title_full Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats
title_fullStr Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats
title_full_unstemmed Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats
title_short Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats
title_sort intermittent ibandronate maintains bone mass, bone structure, and biomechanical strength of trabecular and cortical bone after discontinuation of parathyroid hormone treatment in ovariectomized rats
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486915/
https://www.ncbi.nlm.nih.gov/pubmed/28246925
http://dx.doi.org/10.1007/s00223-017-0255-6
work_keys_str_mv AT takedasatoshi intermittentibandronatemaintainsbonemassbonestructureandbiomechanicalstrengthoftrabecularandcorticalboneafterdiscontinuationofparathyroidhormonetreatmentinovariectomizedrats
AT sakaisadaoki intermittentibandronatemaintainsbonemassbonestructureandbiomechanicalstrengthoftrabecularandcorticalboneafterdiscontinuationofparathyroidhormonetreatmentinovariectomizedrats
AT tanakakeisuke intermittentibandronatemaintainsbonemassbonestructureandbiomechanicalstrengthoftrabecularandcorticalboneafterdiscontinuationofparathyroidhormonetreatmentinovariectomizedrats
AT tomizawaharuna intermittentibandronatemaintainsbonemassbonestructureandbiomechanicalstrengthoftrabecularandcorticalboneafterdiscontinuationofparathyroidhormonetreatmentinovariectomizedrats
AT serizawakenichi intermittentibandronatemaintainsbonemassbonestructureandbiomechanicalstrengthoftrabecularandcorticalboneafterdiscontinuationofparathyroidhormonetreatmentinovariectomizedrats
AT yogokenji intermittentibandronatemaintainsbonemassbonestructureandbiomechanicalstrengthoftrabecularandcorticalboneafterdiscontinuationofparathyroidhormonetreatmentinovariectomizedrats
AT urayamakoji intermittentibandronatemaintainsbonemassbonestructureandbiomechanicalstrengthoftrabecularandcorticalboneafterdiscontinuationofparathyroidhormonetreatmentinovariectomizedrats
AT hashimotojunko intermittentibandronatemaintainsbonemassbonestructureandbiomechanicalstrengthoftrabecularandcorticalboneafterdiscontinuationofparathyroidhormonetreatmentinovariectomizedrats
AT endokoichi intermittentibandronatemaintainsbonemassbonestructureandbiomechanicalstrengthoftrabecularandcorticalboneafterdiscontinuationofparathyroidhormonetreatmentinovariectomizedrats
AT matsumotoyoshihiro intermittentibandronatemaintainsbonemassbonestructureandbiomechanicalstrengthoftrabecularandcorticalboneafterdiscontinuationofparathyroidhormonetreatmentinovariectomizedrats